Answers are grounded in this paper and cite their sources.
For over a decade virtually all A(H3N2) influenza viruses have been resistant to the adamantane class of antivirals. However, during the 2017 influenza season in Australia, 15/461 (3.3%) adamantane-sensitive A(H3N2) viruses encoding serine at residue 31 of the M2 protein were detected, more than the total number identified globally during the last 6 years. A return to wide circulation of adamantane-sensitive A(H3N2) viruses would revive the option of using these drugs for treatment and prophylaxis.
No takes yet. Share an insight, caveat, or question.
Hurt et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: